Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Sep;13(7):1205-1216.
doi: 10.1002/ueg2.70055. Epub 2025 Jun 4.

Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Nicola Pugliese  1   2 , Ivan Arcari  1   2 , Federica Cerini  3   4 , Rosa Lombardi  5   6 , Federica Turati  4 , Grazia Pennisi  7 , Matteo Soleri  1   2 , Simone Rocchetto  3   4 , Diletta De Deo  1   2 , Michele Sagasta  1   8 , Chiara Masetti  1   2 , Anna Ludovica Fracanzani  5   6 , Salvatore Petta  7 , Carlo La Vecchia  4 , Mauro Viganò  9 , Alessio Aghemo  1   2
Affiliations
Multicenter Study

Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Nicola Pugliese et al. United European Gastroenterol J. 2025 Sep.

Abstract

Background and aims: Weight loss is an effective therapeutic strategy for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to identify factors that predict relevant weight loss, defined as at least 7% of initial body weight, in MASLD outpatients.

Method: We retrospectively included all MASLD patients referred to four Italian tertiary centers between January 2019 and December 2021. Patients received lifestyle modification advice according to current guidelines, with reassessment of anthropometric measures after 18-24 months.

Results: A total of 897 patients were included. The majority were male (57%) with a mean age of 61.6 ± 13.3 years and a mean baseline body mass index (BMI) of 30.3 ± 4.5 kg/m2. Comorbidities included type 2 diabetes (T2D; 36%), arterial hypertension (54.7%) and dyslipidemia (55.2%). Over a median observation period of 21 months, 164 (18.3%) patients achieved relevant weight loss. Multiple adjusted regression analysis identified baseline BMI between 30 and 34.9 kg/m2 (odds ratio, OR = 1.95, 95% confidence interval, CI: 1.30-2.95) or ≥ 35 kg/m2 (OR = 2.08, 95% CI: 1.21-3.57), use of GLP-1 agonists for T2D (OR 1.85, 95% CI: 1.19-3.80), bilirubin levels ≥ 1.2 mg/dL (OR 2.12, 95% CI: 1.29-3.51) nutritionist support (OR 2.04, 95% CI: 1.12-3.71) and liver stiffness measurement (LSM) ≥ 10 kPa (OR 1.70, 95% CI: 1.07-2.70) as independent predictors of relevant weight loss.

Conclusions: Baseline BMI ≥ 30 kg/m2, use of GLP-1 agonists, elevated bilirubin levels, support from a nutritionist and LSM ≥ 10 kPa are significant predictors of relevant weight loss in MASLD patients. These findings underscore the importance of personalized interventions in MASLD management.

Keywords: GLP‐1 agonists; MASLD; diet; exercise; lifestyle modification; metabolic syndrome; obesity; steatotic liver disease; type 2 diabetes; weight loss.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Percent change in body weight at the follow‐up visit. Patients with a change in body weight within −7% to +7% were included in the “no change” group.
See this image and copyright information in PMC

References

    1. Rinella M. E., Lazarus J. V., Ratziu V., et al., “A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature,” Journal of Hepatology 79, no. 6 (2023): 1542–1556, 10.1016/j.jhep.2023.06.003. - DOI - PubMed
    1. Targher G., Byrne C. D., and Tilg H., “MASLD: A Systemic Metabolic Disorder With Cardiovascular and Malignant Complications,” Gut 73, no. 4 (March 2024): 691–702, 10.1136/gutjnl-2023-330595. - DOI - PubMed
    1. Bansal S. K. and Bansal M. B., “Pathogenesis of MASLD and MASH – Role of Insulin Resistance and Lipotoxicity,” supplement, Alimentary Pharmacology & Therapeutics 59, no. S1 (2024): S10–S22, 10.1111/apt.17930. - DOI - PubMed
    1. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) , “EASL‐EASD‐EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD),” Journal of Hepatology 81, no. 3 (2024): 492–542, 10.1016/j.jhep.2024.04.031. - DOI - PubMed
    1. Rinella M. E., Neuschwander‐Tetri B. A., Siddiqui M. S., et al., “AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease,” Hepatology (Baltimore, Md.) 77, no. 5 (2023): 1797–1835, 10.1097/HEP.0000000000000323. - DOI - PMC - PubMed

Publication types